The fact that this AMPLIFY trial is for diagnostics and not therapy, I'd assume the entire trial will come to a much quicker conclusion relatively speaking.
What is the rate determining step for the trial?
Presumably lesions identified by the imaging requires follow up biopsies - is that what will take all the time?
Its an unfortunate fact that this BCR cohort is relatively large (and thus the market potential is large for a superior diagnostic imaging agent that is also safe) and thus recruitment should not be an issue.
Ann: First patient imaged in Phase III AMPLIFY trial, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.23 |
Change
0.070(3.24%) |
Mkt cap ! $716.6M | |||
| Open | High | Low | Value | Volume |
| $2.15 | $2.29 | $2.13 | $4.198M | 1.899M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4477 | $2.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.23 | 9998 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |